🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial

RecruitingNAAges 18 Years - 45 YearsFemaleKhyber Medical University Peshawar
NCT07747909 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This randomized controlled clinical trial aims to evaluate the effect of orlistat on the metabolic and hormonal features of women with polycystic ovary syndrome (PCOS). Eligible women diagnosed with PCOS according to the Rotterdam criteria will be randomly assigned to receive either orlistat plus standard lifestyle advice or placebo plus standard lifestyle advice for three months. The study will assess the effect of orlistat on hormonal parameters, glucose metabolism, lipid profile, liver function, anthropometric measures, non-alcoholic fatty liver disease, and quality of life to determine its effectiveness as an adjunctive treatment for women with PCOS.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Females aged 18-45 years. * Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam Criteria (presence of any two of the following): * Oligomenorrhea or amenorrhea. * Clinical or biochemical hyperandrogenism. * Polycystic ovaries on ultrasonography. * Body mass index (BMI) between 18.5 and 35 kg/m² (Asian criteria). Exclusion Criteria: * Current or recent use of oral contraceptives, ovulation induction medications, anti-obesity medications, cholesterol-lowering medications, or other therapies/supplements known to affect insulin physiology or androgen metabolism (e.g., inositols, curcumin, lipoic acid, cinnamon, gymnemic, or other botanical extracts). * Women undergoing in vitro fertilization (IVF) treatment. * Known congenital adrenal hyperplasia, thyroid disorders, hyperprolactinemia, or diabetes mellitus. * Presence of severe renal or liver disease. * Menopausal, pregnant, or breastfeeding women. * Anti-Müllerian Hormone (AMH) \< 0.7 ng/mL.
💊

What it tests

  • Orlistat
  • Placebo
  • Standard Lifestyle Advice
📍

Where

1 site
Ayub Teaching Hospital
Abbottābād, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy